Mohammed K. Alhaidar

Mohammed K. Alhaidar


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMohammed K. Alhaidar
Mohammed K. Alhaidar
SASumayyah Abumurad
Sumayyah Abumurad
BSBetty Soliven
Betty Soliven
KRKourosh Rezania
Kourosh Rezania
Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in humans. Substantial progress has been made in the treatment of MG in the last century, resulting in a change of its natural course from a disease with poor prognosis with a high mortality rate in the early 20th century to a treatable condition with a large proportion of patients attaining very good disease control. This review summarizes the current treatment options for MG, including non-immunosuppressive and immunosuppressive treatments, as well as thymectomy and targeted immunomodulatory drugs.